⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

Official Title: Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

Study ID: NCT03220932

Study Description

Brief Summary: With 4,600 new cases in France in 2012, ovarian cancer is the seventh most common cancer in women and the fourth cause of mortality by cancer. Despite a high response rate to initial treatment, most patients will relapse within 2 years. No standard treatment has yet been established for patients with recurrent ovarian cancer. Most patients with such recurrences are currently treated with new combinations of systemic chemotherapy. A repeated laparotomy with complete cytoreduction is also an option that several authors have used to obtain median survival rates of more than 30 months. Twenty five percent of patients experiencing relapse present with platinum-resistant recurrence, occurring less than 6 months after chemotherapy completion. Recently, Pujade et al. showed that adding bevacizumab to chemotherapy significantly improves progression-free survival (PFS) in this subgroup of patients with poor prognoses (16.6 months versus 13.3 months in women treated with chemotherapy alone). Three case control studies have compared systemic chemotherapy and CRS (Cytoreduction Surgery) alone versus CRS plus HIPEC in patients with recurrent disease. They showed significantly improved results with the addition of HIPEC. In the French registry that included 474 patients with recurrence and peritoneal carcinomatosis, the median PFS was 13.8 months for platinum-resistant patients and 13 months for platinum-sensitive patients. Our hypothesis is that surgery would reduce the tumor burden and consequently the number of platinum-resistant tumor clones and that HIPEC would control the microscopic residual disease by increasing the tumor cell cytotoxicity. We assume that adding a locoregional treatment to an "Aurelia-like" systemic treatment would improve the PFS. We aim to assess the benefit of adding surgery and HIPEC to the treatment of first or second platinum-resistant recurrence compared to chemotherapy + bevacizumab.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Centre Hospitalier Universitaire Jean Minjoz, Besançon, , France

Centre Hospitalier Universitaire Jean Minjoz, Besançon, , France

Centre Oscar Lambret, Lille, , France

CHRU Claude Huriez, Lille, , France

Centre Léon Bérard, Lyon, , France

Centre Léon Bérard, Lyon, , France

Institut du Cancer de Montpellier, Montpellier, , France

Institut du Cancer de Montpellier, Montpellier, , France

Centre Hospitalier Universitaire L'Archet II, Nice, , France

Centre Hospitalier Universitaire L'Archet II, Nice, , France

Centre Hospitalier Universitaire L'Archet II, Nice, , France

Hôpital Européen Georges Pompidou - APHP, Paris, , France

Centre Hospitalier Lyon Sud, Pierre-benite, , France

Centre Hospitalier Lyon Sud, Pierre-Bénite, , France

Centre Hospitalier Universitaire de Poitiers, Poitiers, , France

Centre Hospitalier Universitaire de St Etienne, Saint-priest-en-jarez, , France

Centre Hospitalier Universitaire de St Etienne, Saint-Priest-en-Jarez, , France

Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, , France

Centre Hospitalier Universitaire Hautepierre, Strasbourg, , France

Centre Hospitalier Universitaire Hautepierre, Strasbourg, , France

Centre Hospitalier Universitaire Hautepierre, Strasbourg, , France

Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandœuvre-lès-Nancy, , France

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: